MicroRNA-26 Family in Human Diseases: Context-Dependent Regulation, Biomarker Potential, and Preclinical Nano-Delivery Strategies
Year: 2026
Type: review
Abstract: Purpose: This review aims to summarize the expression patterns, molecular mechanisms, and preclinical nanodelivery strategies of microRNA-26 (miR-26) family members, and to critically evaluate their potential as biomarker candidates and preclinical therapeutic targets in human diseases, including cancers, cardiovascular diseases, metabolic disorders, and neurodegenerative conditions. Methods: A structured narrative review was performed in PubMed, Web of Science, Scopus, and Google Scholar from database inception to August 2026. Peer-reviewed original articles and reviews in English were included. Data on miR-26 isoform expression, target genes, signaling pathways, therapeutic modulators, and nanocarrier systems were extracted and narratively synthesized. A four-tier evidence classification system (Levels I-IV) was applied to distinguish well-established findings from speculative or inferred associations. Results: miR-26 family members-predominantly miR-26a-5p and miR-26b-5p-are highly conserved small non-coding RNAs that post-transcriptionally regulate proliferation, differentiation, apoptosis, metabolism, and immunity in an isoform-specific and context-dependent manner. In most solid tumors, miR-26a-5p and miR-26b-5p are downregulated and function as tumor suppressors, although context-dependent oncogenic roles exist. Circulating and tissue miR-26 isoform levels show statistically significant associations with diagnosis, prognosis, and treatment response in several cancers, supporting their utility as biomarker candidates. However, direct miR-26 mimics or inhibitors remain exclusively preclinical, with no human clinical trials initiated to date. Lipid-, polymer-, and inorganic-based nanocarriers are being explored in preclinical models, but their precision, safety, and biodistribution require systematic validation. Clinical-stage agents targeting downstream effectors of miR-26-regulated pathways do not constitute direct miR-26 modulation and should not be presented as miR-26 therapeutics. Conclusion: miR-26 family members serve as versatile regulatory hubs and biologically plausible biomarker and preclinical therapeutic target candidates. At present, miR-26 should be viewed primarily as a validated biomarker associate and a promising preclinical target-not as an established therapeutic modality. CRISPRa, microbiome-miR-26 interactions, and AI-assisted nanorobots remain future hypotheses rather than established translational strategies.
DOI: 10.2147/ijn.s642611
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,836
OpenAlex ID: W7224527591